Antibody formulations
Patent Information
- Authority / Receiving Office
- US · United States
- Current Assignee / Owner
- GENENTECH INC
- Publication Date
- 2006-04-27
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] This is a non-provisional application filed under 37 CFR 1.53(b) claiming priority to provisional application 60 / 620,413 filed Oct. 20, 2004, the contents of which are incorporated herein by referenceFIELD OF THE INVENTION
[0002] The present invention concerns antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab). BACKGROUND OF THE INVENTION
[0003] In the past ten years, advances in biotechnology have made it possible to produce a variety of proteins for pharmaceutical applications using recombinant DNA techniques. Because proteins are larger and more complex than traditional organic and inorganic drugs (i.e. possessing multiple functional groups in addition to complex three-dimensional structures), the formulation of such proteins poses special probl...